Valneva SE (NASDAQ:VALN) Sees Significant Decrease in Short Interest

Valneva SE (NASDAQ:VALN) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 14,500 shares, a decline of 69.9% from the October 31st total of 48,200 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 20,100 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC lifted its position in shares of Valneva SE (NASDAQ:VALN) by 42.3% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 88,252 shares of the company’s stock after buying an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 as of its most recent SEC filing. Institutional investors own 11.39% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright cut their price objective on Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, October 11th.

Valneva Stock Performance

Shares of NASDAQ:VALN traded down $0.01 during trading on Wednesday, reaching $3.99. 11,208 shares of the stock were exchanged, compared to its average volume of 12,619. Valneva has a 12 month low of $3.95 and a 12 month high of $11.96. The stock has a 50-day moving average price of $5.58 and a 200-day moving average price of $6.90. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The firm has a market cap of $324.19 million, a PE ratio of -30.77 and a beta of 2.17.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.